Dr Jyoti Choudhary's research focuses on understanding how the organisation and dynamics of protein networks underpin cancer progression and resistance. She also investigates the impact of mutations and genetic variation on the proteome and protein attributes using quantitative mass spectrometry. Toward this goal, her research group develops novel experimental and computational proteomics and proteogenomic techniques.
She received her PhD in biological mass spectrometry under the guidance of Professor Howard Morris FRS at Imperial College London. She joined the Bioanalytical Sciences division in GlaxoWellcome as a senior scientist and was subsequently selected as a group leader in the CellMap project - a technology incubator unit founded to pursue the development of cutting edge proteomics technologies for drug discovery applications.
This highly successful and reputed unit was spun out of GlaxoSmithKline (GSK), and she became a founding member of Cellzome AG. This leading biotech company developed and applied interaction and chemical proteomics technology for target identification and drug development.
She joined the Wellcome Trust Sanger Institute in 2004, to pursue her research in interaction proteomics and proteogenomics. Her group implemented endogenous gene tagging, eTAP, in mouse stem cells and applied it to systematically study native protein complexes in a range of cell types and tissues. They further developed open access computational tools and data analysis pipelines to integrate proteomics data with genomics. These were then used to refine annotation of the mammalian and malaria genomes, as well as to study the impact of genetic variation on protein networks.
Moving to the ICR in 2017, Dr Choudhary is currently Head of the Proteomics Core Facility and Career Faculty Leader, where she leads a team applying leading edge proteomics, and proteogenomics technologies to further cancer research. Additionally she is a visiting scientist at Imperial College London and at the Wellcome Trust Sanger Institute.